First Hawaiian Bank’s Amneal Pharmaceuticals AMRX Stock Holding History

First Hawaiian Bank’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-268	Closed	-$4K	–	809
2019 Q1	$4K	Buy	268 +68	+34%	+$899	﹤0.01%	1541
2018 Q4	$3K	Sell	200 -129	-39%	-$2.33K	﹤0.01%	1658
2018 Q3	$7K	Buy	+329	New	+$6.92K	﹤0.01%	1597

Other funds holding AMRX

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

First Hawaiian Bank's AMRX Position: Q2 2019 in Review

First Hawaiian Bank sold out of Amneal Pharmaceuticals (AMRX) in Q2 2019, closing a stake of 268 shares — an estimated $4K sold.

First Hawaiian Bank first reported a position in AMRX in Q3 2018 and held it in 3 quarters. The position peaked at $7K in Q3 2018. 129 funds tracked by Wall St. Rank hold AMRX as of Q2 2019.

First Hawaiian Bank reported no remaining Amneal Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
First Hawaiian Bank sold 268 Amneal Pharmaceuticals shares in Q2 2019, an estimated $4K.
First Hawaiian Bank first reported a position in Amneal Pharmaceuticals in Q3 2018 and held it in 3 quarters.
First Hawaiian Bank's Amneal Pharmaceuticals position peaked at $7K in Q3 2018.
129 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2019.

Based on First Hawaiian Bank's 13F filing for Q2 2019, filed 15 Jul 2019.